Dementia Common in Down Syndrome Patients Aged ≥55
More than half of individuals with Down syndrome aged 55 years or older have dementia claims and 32.7% have Alzheimer disease (AD) claims.
More than half of individuals with Down syndrome aged 55 years or older have dementia claims and 32.7% have Alzheimer disease (AD) claims.
Low and high hemoglobin levels were associated with increased risk for dementia, white matter hyperintensity volume, and structural connectivity.
Pupillary dilation during cognitive tasks is associated with Alzheimer disease polygenic risk score.
Most cerebrovascular risk factors are linked to a higher risk for subsequent diagnosis of Parkinson disease.
These products may prevent patients from seeking appropriate treatment.
Researchers identified current gaps in aging and diversity research and identified future directions that research should take.
There may be possible benefits for long-term hormone therapy, but the results are not definitive.
Witnessing a loved one succumb to Alzheimers disease (AD) is one of the most difficult experiences a person has to deal with. Signs of the disease appear slowly at first. The affected individual may forget a word or misplace an object, which is something that happens to everyone from time to time. But then it gets more serious.
Rapidly emerging technologies, novel imaging techniques, and the development of new therapies and new genes have given researchers and clinicians an extraordinary ability to explore the brain at the cellular, genetic, and neural levels.
A new online project led by researchers at UC San Francisco promises to dramatically cut the time and cost of conducting clinical trials for brain diseases, while also helping scientists analyze and track the brain functions of thousands of volunteers over time.
With easy online registration, the Brain Health Registry is designed to create a ready pool of research subjects for studies on neurological diseases, such as Alzheimer’s and Parkinson’s, as well as depression, post-traumatic stress disorder and many other brain ailments. About one third of the cost of running a clinical trial comes from having to recruit patients, and many trials fail or are delayed because of it.